Search Results - "Brittain, Erica H."

Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis by Carter, Melody C., MD, Clayton, Sarah T., BS, Komarow, Hirsh D., MD, Brittain, Erica H., PhD, Scott, Linda M., NP, Cantave, Daly, MSN, Gaskins, Donna M., BSN, Maric, Irina, MD, Metcalfe, Dean D., MD

“…Background The management of children with pediatric mastocytosis poses a challenge. This is because there is limited information as to the application of…”
Get full text

A primer on strong vs weak control of familywise error rate by Proschan, Michael A., Brittain, Erica H.

“…Multiple comparison adjustments have a long history, yet confusion remains about which procedures control type 1 error rate in a strong sense and how to show…”
Get full text

A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis by Carter, Melody C., Maric, Irina, Brittain, Erica H., Bai, Yun, Lumbard, Keith, Bolan, Hyejeong, Cantave, Daly, Scott, Linda M., Metcalfe, Dean D.

“…Idiopathic anaphylaxis (IA) is a diagnosis of exclusion, thus taking away the option of therapeutic management focused on eliminating the inciting agent…”
Get full text

Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease by Dorjbal, Batsukh, Stinson, Jeffrey R., Ma, Chi A., Weinreich, Michael A., Miraghazadeh, Bahar, Hartberger, Julia M., Frey-Jakobs, Stefanie, Weidinger, Stephan, Moebus, Lena, Franke, Andre, Schäffer, Alejandro A., Bulashevska, Alla, Fuchs, Sebastian, Ehl, Stephan, Limaye, Sandhya, Arkwright, Peter D., Briggs, Tracy A., Langley, Claire, Bethune, Claire, Whyte, Andrew F., Alachkar, Hana, Nejentsev, Sergey, DiMaggio, Thomas, Nelson, Celeste G., Stone, Kelly D., Nason, Martha, Brittain, Erica H., Oler, Andrew J., Veltri, Daniel P., Leahy, T. Ronan, Conlon, Niall, Poli, Maria C., Borzutzky, Arturo, Cohen, Jeffrey I., Davis, Joie, Lambert, Michele P., Romberg, Neil, Sullivan, Kathleen E., Paris, Kenneth, Freeman, Alexandra F., Lucas, Laura, Chandrakasan, Shanmuganathan, Savic, Sinisa, Hambleton, Sophie, Patel, Smita Y., Jordan, Michael B., Theos, Amy, Lebensburger, Jeffrey, Atkinson, T. Prescott, Torgerson, Troy R., Chinn, Ivan K., Milner, Joshua D., Grimbacher, Bodo, Cook, Matthew C., Snow, Andrew L.

“…Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream…”
Get full text

Interpreting p-Values and Confidence Intervals Using Well-Calibrated Null Preference Priors by Fay, Michael P., Proschan, Michael A., Brittain, Erica H., Tiwari, Ram

“…We propose well-calibrated null preference priors for use with one-sided hypothesis tests, such that resulting Bayesian and frequentist inferences agree. Null…”
Get full text

Finite sample pointwise confidence intervals for a survival distribution with right-censored data by Fay, Michael P., Brittain, Erica H.

“…We review and develop pointwise confidence intervals for a survival distribution with right‐censored data for small samples, assuming only independence of…”
Get full text

Causal estimands and confidence intervals associated with Wilcoxon‐Mann‐Whitney tests in randomized experiments by Fay, Michael P., Brittain, Erica H., Shih, Joanna H., Follmann, Dean A., Gabriel, Erin E.

“…Although the P value from a Wilcoxon‐Mann‐Whitney test is used often with randomized experiments, it is rarely accompanied with a causal effect estimate and…”
Get full text

On Causal Inferences for Personalized Medicine: How Hidden Causal Assumptions Led to Erroneous Causal Claims About the D-Value by Greenland, Sander, Fay, Michael P., Brittain, Erica H., Shih, Joanna H., Follmann, Dean A., Gabriel, Erin E., Robins, James M.

“…Personalized medicine asks if a new treatment will help a particular patient, rather than if it improves the average response in a population. Without a causal…”
Get full text

Pointwise confidence intervals for a survival distribution with small samples or heavy censoring by Fay, Michael P, Brittain, Erica H, Proschan, Michael A

“…We propose a beta product confidence procedure (BPCP) that is a non-parametric confidence procedure for the survival curve at a fixed time for right-censored…”
Get full text

Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms by Chovanec, Jack, Tunc, Ilker, Hughes, Jason, Halstead, Joseph, Mateja, Allyson, Liu, Yihui, O’Connell, Michael P., Kim, Jiwon, Park, Young Hwan, Wang, Qinlu, Le, Quang, Pirooznia, Mehdi, Trivedi, Neil N., Bai, Yun, Yin, Yuzhi, Hsu, Amy P., McElwee, Joshua, Lassiter, Sheryce, Nelson, Celeste, Bandoh, Judy, DiMaggio, Thomas, Šelb, Julij, Rijavec, Matija, Carter, Melody C., Komarow, Hirsh D., Sabato, Vito, Steinberg, Joshua, Hafer, Kurt M., Feuille, Elizabeth, Hourigan, Christopher S., Lack, Justin, Khoury, Paneez, Maric, Irina, Zanotti, Roberta, Bonadonna, Patrizia, Schwartz, Lawrence B., Milner, Joshua D., Glover, Sarah C., Ebo, Didier G., Korošec, Peter, Caughey, George H., Brittain, Erica H., Busby, Ben, Metcalfe, Dean D., Lyons, Jonathan J.

“…•Characterizing genetic regulation of tryptase expression redefines clinical laboratory reference ranges based on TPSAB1 replication number.•Individualized…”
Get full text

Comments on Berry et al.’s response-adaptive randomization platform trial for Ebola by Brittain, Erica H, Proschan, Michael A

Get full text

A valid formulation of the analysis of noninferiority trials under random effects meta-analysis by Brittain, Erica H, Fay, Michael P, Follmann, Dean A

“…A noninferiority (NI) trial is sometimes employed to show efficacy of a new treatment when it is unethical to randomize current patients to placebo because of…”
Get full text

Does treatment effect depend on control event rate? Revisiting a meta-analysis of suicidality and antidepressant use in children by Proschan, Michael A, Brittain, Erica H, Fay, Michael P

“…Background Weisberg et al. (Clin Trials 2009, 6: 109—18) illustrate that entry criteria in randomized trials can lead to results that are biased for the target…”
Get full text

Response to commentary by Proshan, Michael A, Brittain, Erica H, Fay, Michael P

“…A response to the commentary "Apparent relationship between relative risk and control rate: statistical artifact or selection bias?" by y by Weisburg, Hayden,…”
Get full text

Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease by Dorjbal, Batsukh, Stinson, Jeffrey R., Ma, Chi A., Weinreich, Michael A., Miraghazadeh, Bahar, Hartberger, Julia M., Frey-Jakobs, Stefanie, Weidinger, Stephan, Moebus, Lena, Franke, Andre, Schäffer, Alejandro A., Bulashevska, Alla, Fuchs, Sebastian, Ehl, Stephan, Limaye, Sandhya, Arkwright, Peter D., Briggs, Tracy A., Langley, Claire, Bethune, Claire, Whyte, Andrew F., Alachkar, Hana, Nejentsev, Sergey, DiMaggio, Thomas, Nelson, Celeste G., Stone, Kelly D., Nason, Martha, Brittain, Erica H., Oler, Andrew J., Veltri, Daniel P., Leahy, T. Ronan, Conlon, Niall, Poli, Maria C., Borzutzky, Arturo, Cohen, Jeffrey I., Davis, Joie, Lambert, Michele P., Romberg, Neil, Sullivan, Kathleen E., Paris, Kenneth, Freeman, Alexandra F., Lucas, Laura, Chandrakasan, Shanmuganathan, Savic, Sinisa, Hambleton, Sophie, Patel, Smita Y, Jordan, Michael B., Theos, Amy, Lebensburger, Jeffrey, Atkinson, T. Prescott, Torgerson, Troy R., Chinn, Ivan K., Milner, Joshua D., Grimbacher, Bodo, Cook, Matthew C., Snow, Andrew L.

“…This description of a large cohort of patients broadens the spectrum of clinical disease phenotypes linked to CARD11 DN mutations, including atopy, cutaneous…”
Get full text

Case-control study of galactorrhea and its relationship to the use of oral contraceptives by Taler, S J, Coulam, C B, Annegers, J F, Brittain, E H

“…A case-control study was performed to determine the relationship between galactorrhea and the use of oral contraceptives as well as other risk factors. The…”
Get more information

Optimization of Multistage Testing Times and Critical Values in Clinical Trials by Brittain, Erica H., Bailey, Kent R.

“…Optimal critical values and times of intermediate testing points are determined to minimize expected sample size in a variety of situations. Two-stage and…”
Get full text